Reports

Ideas That Generate Results

List of Figures:
 
Figure 5-1: Global - Breakup of Cancer Prevalence by Region (%), 2015
Figure 5-2: Global - Breakup of Cancer Prevalence by Region (%), 2025
Figure 6-1: Global - T-Cell Immunotherapy Pipeline Analysis by Vectors (%), 2016
Figure 6-2: Global - T-Cell Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 6-3: Global - T-Cell Immunotherapy Pipeline Analysis by Therapeutic Indication (%), 2016
Figure 6-4: Global - T-Cell Immunotherapy Pipeline Analysis by Technology (%), 2016
Figure 6-5: Global - T-Cell Immunotherapy Pipeline Analysis by Key Players (%), 2016
Figure 6-6: Global - T-Cell Immunotherapy Pipeline Analysis by Geography (%), 2016
 
List of Tables:
 
Table 4-1: Global - Major Investments & Grants in T-Cell Immunotherapy (Million US$)
Table 4-2: Global - Major Venture Capitalist Investment in T-Cell Immunotherapy (Million US$)
Table 5-1: Global - Cancer Prevalence (Million), 2015 & 2025
Table 5-2: Global - Leukemia Prevalence (‘000), 2015 & 2025       
Table 5-3: North America - Leukemia Prevalence (‘000), 2015 & 2025
Table 5-4: Europe - Leukemia Prevalence (‘000), 2015 & 2025
Table 5-5: Asia-Pacific - Leukemia Prevalence (‘000), 2015 & 2025
Table 5-6: Rest of the World - Leukemia Prevalence (‘000), 2015 & 2025
Table 5-7: Global - Lymphoma Prevalence (‘000), 2015 & 2025
Table 5-8: North America - Lymphoma Prevalence (‘000), 2015 & 2025
Table 5-9: Europe - Lymphoma Prevalence (‘000), 2015 & 2025
Table 5-10: Asia-Pacific - Lymphoma Prevalence (‘000), 2015 & 2025      36
Table 5-11: Rest of the World - Lymphoma Prevalence (‘000), 2015 & 2025
Table 5-12: Global - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 5-13: North America - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 5-14: Europe - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 5-15: Asia-Pacific - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 5-16: Rest of the World - Multiple Myeloma Prevalence (‘000), 2015 & 2025
Table 5-17: Global - Melanoma Prevalence (‘000), 2015 & 2025
Table 5-18: North America - Melanoma Prevalence (‘000), 2015 & 2025
Table 5-19: Europe - Melanoma Prevalence (‘000), 2015 & 2025
Table 5-20: Asia-Pacific - Melanoma Prevalence (‘000), 2015 & 2025
Table 5-21: Rest of the World - Melanoma Prevalence (‘000), 2015 & 2025
Table 5-22: Global - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 5-23: North America - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 5-24: Europe - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 5-25: Asia-Pacific - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 5-26: Rest of the World - Bladder Cancer Prevalence (‘000), 2015 & 2025
Table 5-27: Global - Kidney Cancer Prevalence (‘000), 2015 & 2025        
Table 5-28: North America - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 5-29: Europe - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 5-30: Asia-Pacific - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 5-31: Rest of the World - Kidney Cancer Prevalence (‘000), 2015 & 2025
Table 5-32: Global - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 5-33: North America - Ovarian Cancer Prevalence (‘000), 2015 & 2025    
Table 5-34: Europe - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 5-35: Asia-Pacific - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 5-36: Rest of the World - Ovarian Cancer Prevalence (‘000), 2015 & 2025
Table 5-37: Global - Breast Cancer Prevalence (‘000), 2015 & 2025
Table 5-38: North America - Breast Cancer Prevalence (‘000), 2015 & 2025      
Table 5-39: Europe - Breast Cancer Prevalence (‘000), 2015 & 2025        
Table 5-40: Asia-Pacific - Breast Cancer Prevalence (‘000), 2015 & 2025 
Table 5-41: Rest of the World - Breast Cancer Prevalence (‘000), 2015 & 2025  
Table 5-42: Global - Lung Cancer Prevalence (‘000), 2015 & 2025  
Table 5-43: North America - Lung Cancer Prevalence (‘000), 2015 & 2025         
Table 5-44: Europe - Lung Cancer Prevalence (‘000), 2015 & 2025 
Table 5-45: Asia-Pacific - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 5-46: Rest of the World - Lung Cancer Prevalence (‘000), 2015 & 2025
Table 6-1: Global T-Cell Immunotherapy Pipeline
Table 7-1: Global - Major Venture Capitalist Investment in T-Cell Immunotherapy (Million US$)
Table 7-2: Global - Major IPO Raised in T-Cell Immunotherapy (Million US$), 2014-2016
Table 8-1: Adaptimmune Therapeutics plc - Total Revenue (Million US$), FY 2014 & FY 2015
Table 8-2: Adaptimmune Therapeutics plc - T-Cell Immunotherapy Pipeline    
Table 8-3: Juno Therapeutics, Inc. - Total Revenue (Million US$), 2015  
Table 8-4: Juno Therapeutics, Inc. - T-Cell Immunotherapy Pipeline      
Table 8-5: Kite Pharma, Inc. - Total Revenue (Million US$), 2015  
Table 8-6: Kite Pharma, Inc. - T-Cell Immunotherapy Pipeline     
Table 8-7: Novartis - Net Sales (Million US$), 2013, 2014 & 2015   
Table 8-8: Novartis - T-Cell Immunotherapy Pipeline
Table 8-9: Tessa Therapeutics Pte Ltd. - T-Cell Immunotherapy Pipeline
Table 8-10: Gradalis, Inc. - T-Cell Immunotherapy Pipeline
Table 8-11: Immunovative Therapies, Ltd. - T-Cell Immunotherapy Pipeline
Table 8-12: Lion Biotechnologies, Inc. - T-Cell Immunotherapy Pipeline
Table 8-13: Atara Biotherapeutics, Inc. - T-Cell Immunotherapy Pipeline
Table 8-14: Celgene Corporation - Total Revenue (Million US$), 2013, 2014 & 2015
Table 8-15: Celgene Corporation - T-Cell Immunotherapy Pipeline
Table 8-16: Cellular Biomedicine Group - Total Revenue (Million US$), 2013, 2014 & 2015
Table 8-17: Cellular Biomedicine Group - T-Cell Immunotherapy Pipeline
Table 8-18: GlaxoSmithKline plc. - Group Turnover (Million US$), 2013, 2014 & 2015
Table 8-19: GlaxoSmithKline plc. - T-Cell Immunotherapy Pipeline
Table 8-20: Immunocore Ltd. - T-Cell Immunotherapy Pipeline
Table 8-21: Inovio Pharmaceuticals, Inc. - Revenue (Million US$), 2013, 2014 & 2015
Table 8-22: Inovio Pharmaceuticals, Inc. - T-Cell Immunotherapy Pipeline      
Table 8-23: Cell Medica - T-Cell Immunotherapy Pipeline